

Clinical trials of idrabiotaparinux

TrialResults-center www.trialresultscenter.org

1 pulmonary embolism

Trial	Treatments	Patients	Trials design and methods
idrabiotaparinux vs warfarin			
CASSIOPEA , 2012 [NCT00345618] n=1599/1603 follow-up: 99 days	subcutaneous idrabiotaparinux (starting dose 30 mg) after 5-10 days' enoxaparin 10 mg/kg twice daily for at least 3 months or 6 months dependent on clinical presentation versus adjusted-dose warfarin (target INR 2-3) after 5-10 days' enoxaparin 10 mg/kg twice daily	adults with objectively documented acute symptomatic pulmonary embolism	Parallel groups double-blind 37 countries

More details and results :

- antithrombotics for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q102>

References

CASSIOPEA, 2012:

Bller HR, Gallus AS, Pillion G, Prins MH, Raskob GE Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-9 [22130488] [10.1016/S0140-6736\(11\)61505-5](https://doi.org/10.1016/S0140-6736(11)61505-5)